Euthyrox (levothyroxine) new formulation tablets: monitoring of patients switching between tablets

A Dear Healthcare Professional Letter has been issued by Merck to inform healthcare professionals on the new formulation of Euthyrox tablets. The re-formulated tablets will offer improved stability of the active substance throughout the medicinal product’s shelf life and do not contain lactose. How Euthyrox is taken and monitored remains unchanged. Close monitoring of patients switching to the new formulation of Euthyrox tablets is recommended as thyroid imbalances can be triggered by the switch due to levothyroxine’s narrow therapeutic range. Please refer to the letter for details.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

14 Jan 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.